Ind-Swift Labs releases Q1FY27 earnings call audio recording

0 min read Updated on 17 Aug 2026, 08:50 PM

Reviewed by

Naman SScanX News Team

AI Summary

Ind-Swift Laboratories Limited released the audio recording of its Q1FY27 earnings call on August 17, 2026. The call addressed financial performance for the quarter ended June 30, 2026. The transcript is pending upload to the company website and exchange portals.

*this image is generated using AI for illustrative purposes only.

Ind-Swift Laboratories has made the audio recording of its earnings conference call available to investors. The call was held on Monday, August 17, 2026, to discuss the financial results for the quarter ended June 30, 2026.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The audio file is accessible via the company’s investor relations page under Regulation 46 disclosures.

Transcript Availability

The full transcript of the earnings call will be shared with the Bombay Stock Exchange and the National Stock Exchange of India Limited. It will also be uploaded to the company’s website in due course.

Pardeep Verma, Vice President of Corporate Affairs and Company Secretary at Ind-Swift Laboratories, signed the disclosure letter dated August 17, 2026.

Historical Stock Returns for Ind Swift Laboratories

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.91%	+37.04%	+36.18%	+117.77%	+208.58%	+318.76%

How will the Q2 2026 financial results influence Ind-Swift Laboratories' stock valuation and investor sentiment in the coming quarter?

What specific growth initiatives or R&D projects did management highlight during the call that could drive future revenue streams?

Are there any anticipated changes in dividend policy or share buyback plans based on the current cash flow position discussed in the earnings?

Read Next Article

Ind Swift Laboratories targets ₹1,200 crore revenue by FY29

0 min read Updated on 17 Aug 2026, 02:58 PM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

AI Summary

Ind Swift Laboratories outlines a growth strategy centered on filing 400+ dossiers by FY27. Operating CDMO partnerships with Viatris, Manx, and Arrotex are expected to add ₹200–220 crore in FY27 revenue. The company projects a 20-25% CAGR, aiming to increase total revenue from ₹636 crore to over ₹1,200 crore by FY29.

*this image is generated using AI for illustrative purposes only.

Ind Swift Laboratories plans to file more than 400 dossiers by FY27 to strengthen long-term IP-led revenue visibility. The company expects a compound annual growth rate (CAGR) of 20-25%, projecting revenue to rise from ₹636 crore to over ₹1,200 crore by FY29.

Partnership Revenue Potential

CDMO partnerships with Viatris, Manx, and Arrotex are now operating. These collaborations are anticipated to generate an additional ₹200–220 crore in revenue in FY27.

Partner	Status	Expected Impact
Viatris	Operating	Part of ₹200–220 crore FY27 addition
Manx	Operating	Part of ₹200–220 crore FY27 addition
Arrotex	Operating	Part of ₹200–220 crore FY27 addition

What the Numbers Show

The projected additional revenue from new partnerships represents a significant portion of the company's near-term growth trajectory. With the base revenue at ₹636 crore, the expected ₹200–220 crore incremental income from these three partners alone would account for approximately 31-35% of the current revenue base, highlighting a strong dependency on these specific commercial relationships for FY27 performance.

Historical Stock Returns for Ind Swift Laboratories

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.91%	+37.04%	+36.18%	+117.77%	+208.58%	+318.76%

What specific regulatory or operational risks could delay the filing of the 400+ dossiers by FY27, and how might this impact the projected 20-25% CAGR?

How does Ind Swift Laboratories plan to mitigate the concentration risk associated with deriving 31-35% of its near-term revenue from just three CDMO partners?

Are there indications that Viatris, Manx, or Arrotex have long-term volume commitments beyond FY27, or is there a risk of partnership churn once initial dossiers are filed?